Reversing hypoxic cell chemoresistance in vitro using genetic and small molecule approaches targeting hypoxia inducible factor-1

Molecular Pharmacology

Volumn 69, Issue 2, 2006, Pages 411-418

  Brown, Louisa M ^a   Cowen, Rachel L ^a   Debray, Camille ^a   Eustace, Amanda ^a   Erler, Janine T ^b   Sheppard, Freda C D ^a   Parker, Catriona A ^a   Stratford, Ian J ^a   Williams, Kaye J ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 CYANOQUINOCARCINOL; ANTINEOPLASTIC ANTIBIOTIC; ENHANCED GREEN FLUORESCENT PROTEIN; ETOPOSIDE; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; OXYGEN; QUINOCARMYCIN; QUINOCARMYCIN CITRATE; TOPOTECAN; UNCLASSIFIED DRUG;

ADENOVIRUS; AIR; ANOXIA; ARTICLE; CANCER RESISTANCE; CELL STRAIN HCT116; CHEMOTHERAPY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG TARGETING; GENE TARGETING; GENE THERAPY; HUMAN; HUMAN CELL; HYPOXIC CELL; IC 50; IN VITRO STUDY; MALE; OXYGEN TENSION; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SENSITIZATION; TRANSACTIVATION; TREATMENT FAILURE; TUMOR CELL; TUMOR CELL LINE;

ADENOVIRIDAE; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL HYPOXIA; CELL LINE, TUMOR; CELL NUCLEUS; DRUG RESISTANCE, NEOPLASM; ETOPOSIDE; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; ISOQUINOLINES; NEOPLASMS; OXYGEN; SEQUENCE DELETION; TOPOTECAN; TRANS-ACTIVATION (GENETICS);

EID: 31044444974     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.105.015743     Document Type: Article

References (34)

1. Bardos JI and Ashcroft M (2004) Hypoxia-inducible factor-1 and oncogenic signalling. Bioessays 26:262-269.
2. Birner P, Schindl M, Obermair A, Plank C, Breitenecker G, and Oberhuber G (2000) Overexpression of hypoxia-inducible factor 1α is a marker for an unfavourable prognosis in early-stage invasive cervical cancer. Cancer Res 60:4693-4696.
3. Bos R, van der Groep P, Greijer AE, Shvarts A, Meijer S, Pinedo HM, Semenza GL, van Diest PJ, and van der Wall E (2001) Levels of hypoxia-inducible factor-1alpha during breast carcinogenesis. J Natl Cancer Inst 93:309-314.
4. Chadderton N, Cowen RL, Sheppard FC, Robinson S, Greco O, Scott SD, Stratford IJ, Patterson AV, and Williams KJ (2005) Dual responsive promoters to target therapeutic gene expression to radiation-resistant hypoxic tumor cells. Int J Radiat Biol Oncol Physics 62:213-222.
5. Chen J, Zhao S, Nakada K, Kuge Y, Tamaki N, Okada F, Wang J, Shindo M, Higashino F, Takeda K, et al. (2003) Dominant-negative hypoxia-inducible factor 1 alpha reduces the tumorigenicity of pancreatic cancer cells through the suppression of glucose metabolism. Am J Pathol 162:1283-1291.
6. Comerford KM, Wallace TJ, Karhausen J, Louis NA, Montalto MC, and Colgan S (2002) Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res 62:3387-3394.
7. Cowen RL, Williams KJ, Chinje EC, Jaffar M, Sheppard FC, Telfer BA, Wind NS, and Stratford IJ (2004) Hypoxia targeted gene therapy to increase the efficacy of tirapazamine as an adjuvant to radiotherapy: reversing tumor radioresistance and effecting cure. Cancer Res 64:1396-1402.
8. Erler JT, Cawthorne CJ, Williams KJ, Koritzinsky M, Wouters BG, Wilson C, Miller C, Demonacos C, Stratford IJ, and Dive C (2004) Hypoxia-mediated downregulation of Bid and Bax in tumors occurs via HIF-1-dependent and-independent mechanisms and contributes to drug resistance. Mol Cell Biol 24:2875-2889.
9. Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW, and Giaccia AJ (1996) Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumors. Nature (Lond) 379:88-91.
10. Griffiths JR, McSheehy PM, Robinson SP, Troy H, Chung YL, Leek RD, Williams KJ, Stratford IJ, Harris AL, and Stubbs M (2002) Metabolic changes detected by in vivo magnetic resonance studies of HEPA-1 wild-type tumors and tumors deficient in hypoxia-inducible factor-1∵(HIF-1∵): evidence of an anabolic role for the HIF-1 pathway. Cancer Res 62:688-695.
11. Hopfl G, Wenger RH, Ziegler U, Stallmach T, Gardelle O, Achermann R, Wergin M, Kaser-Hotz B, Saunders HM, Williams KJ, et al. (2002) Rescue of hypoxiainducible factor-1α-deficient tumor growth by wild-type cells is independent of the vascular endothelial growth factor. Cancer Res 62:2962-2970.
12. Jiang B-H, Agani F, Passaniti A, and Semenza GL (1997) V-src induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding VEGF and enolase 1: involvement of HIF-1 in tumor progression. Cancer Res 57:5328-5335.
13. Jiang B-H, Rue E, Wang GL, Roe R, and Semenza GL (1996) Dimerization, DNA binding and transactivation properties of hypoxia-inducible factor-1. J Biol Chem 271:17771-17778.
14. Kung AL, Wang S, Klco JM, Kaelin WG, and Livingston DM (2000) Suppression of tumor growth through disruption of hypoxia-inducible transcription. Nature (Lond) Med 6:1335-1340.
15. Mabjeesh NJ, Escuin D, LaVallee TM, Pribluda VS, Swartz GM, Johnson MS, Willard MT, Zhong H, Simons JW, and Giannakakou P (2003) 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 3:363-375.
16. Maxwell PH, Dachs GU, Gleadle JM, Nicholls LG, Harris AL, Stratford IJ, Hankinson O, Pugh CW, and Ratcliffe PJ (1997) Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. PNAS 94:8104-8109.
17. Metzen E and Ratcliffe PJ (2004) HIF hydroxylation and cellular oxygen sensing. Biol Chem 385:223-230.
18. Rapisarda A, Uranchimeg B, Scudiero DA, Selby M, Sausville EA, Shoemaker RH, and Melillo G (2002) Identification of small molecule inhibitors of hypoxiainducible factor-1 transcriptional activation pathway. Cancer Res 62:4316-4324.
19. Ryan HE, Lo J, and Johnson RS (1998) HIF-α1 is required for solid tumor formation and embryonic vascularisation. EMBO (Eur Mol Biol Organ) J 17:3005-3015.
20. Stoeltzing O, McCarty MF, Wey JS, Fan F, Liu W, Belcheva A, Bucana CD, Semenza GL, and Ellis LM (2004) Role of hypoxia-inducible factor-1α in gastric cancer cell growth, angiogenesis and vessel maturation. J Natl Cancer Inst 96:946-956.
21. Tan C, de Noronha RG, Roecker AJ, Pyrzynska B, Khwaja F, Zhang Z, Zhang H, Teng Q, Nicholson AC, Giannakakou P, et al. (2005) Identification of a novel small-molecule inhibitor of the hypoxia-inducible factor 1 pathway. Cancer Res 65:605-612.
22. Teicher BA (1994) Hypoxia and drug resistance. Cancer Metastasis Rev 13:39-68.
23. Unruh A, Ressel A, Mohamed HG, Johnson RS, Nadrowitz R, Richter E, Katschinski DM, and Wenger RH (2003) The hypoxia-inducible factor-1α is a negative factor for tumor therapy. Oncogene 22:3213-3220.
24. Welsh S, Williams R, Kirkpatrick L, Paine-Murrieta G, and Powis G (2004) Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxiainducible factor-1alpha. Mol Cancer Ther 3:233-244.
25. Wiesener MS and Maxwell PH (2003) HIF and oxygen sensing; as important to life as the air we breathe? Ann Med 35:183-190.
26. Wilbur K and Anderson N (1984) Electrometric and colorimetric determination of carbonic anhydrase. J Biol Chem 176:147-154.
27. 1/S cell cycle arrest in irradiated Li-Fraumeni lymphoblastoid cell lines. Br J Cancer 74:698-703.
28. Williams KJ, Parker CA, and Stratford IJ (2005) Exogenous and endogenous markers of tumor oxygen status. Adv Exp Med Biol, in press.
29. Williams KJ, Telfer BA, Airley RE, Peters HP, Sheridan MR, van der Kogel AJ, Harris AL, and Stratford IJ (2002) A protective role for HIF-1 in response to redox manipulation and glucose deprivation: implications for tumorigenesis. Oncogene 21:282-290.
30. Wood SM, Wiesener MS, Yeates KM, Okada N, Pugh CW, Maxwell PH, and Ratcliffe PJ (1998) Selection and analysis of a mutant cell line defective in the hypoxiainducible factor-1α-subunit (HIF-1α). J Biol Chem 273:8360-8368.
31. Wykoff CC, Beasley NJ, Watson PH, Turner KJ, Pastorek J, Sibtain A, Wilson GD, Turley H, Talks KL, Maxwell PH, et al. (2000) Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res 60:7075-7083.
32. Yeo EJ, Chun YS, Cho YS, Kim J, Lee JC, Kim MS, and Park JW (2003) YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1. J Natl Cancer Inst 95:516-525.
33. Young SD, Marshall RS, and Hill RP (1988) Hypoxia induces DNA overreplication and enhances metastatic potential of murine tumor cells. Proc Natl Acad Sci USA 85:9533-9537.
34. Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, Buechler P, Isaacs WB, Semenza GL, and Simons JW (1999) Overexpression of hypoxiainducible factor 1alpha in common human cancers and their metastases. Cancer Res 59:5830-5835.